Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | SNCA | P37840 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GPR183 | P32249 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2374615 | 1.00 | TRPM8 (0.42) | TRPM8NPC1RAB9APKMMEN1 | |
| SCHEMBL2374607 | 1.00 | TRPM8 (0.42) | TRPM8NPC1RAB9APKMMEN1 | |
| SCHEMBL2374226 | 0.93 | TRPM8 (0.43) | TRPM8NPC1RAB9APKMMEN1 | |
| SCHEMBL2374212 | 0.93 | TRPM8 (0.43) | TRPM8NPC1RAB9APKMMEN1 | |
| SCHEMBL2374220 | 0.93 | TRPM8 (0.43) | TRPM8NPC1RAB9APKMMEN1 | |
| SCHEMBL2376256 | 0.93 | LMNA (0.42) | RAB9AMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL2376249 | 0.93 | LMNA (0.42) | RAB9AMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL2376252 | 0.93 | LMNA (0.42) | RAB9AMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL2374946 | 0.92 | TRPM8 (0.42) | TRPM8NPC1RAB9APKMMEN1 | |
| SCHEMBL2374944 | 0.92 | TRPM8 (0.42) | TRPM8NPC1RAB9APKMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-15 | — | — | US | claimed |
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | CTSA, BECN1, HDAC6 | TRPM8 2184/4885NPC1 1403/4885RAB9A 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.